33780 Federal Register / Vol. 79, No. 113 / Thursday, June 12, 2014 / Notices 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–378] 

Proposed Adjustments to the 

Aggregate Production Quotas for 

Schedule I and II Controlled 

Substances and Assessment of 

Annual Needs for the List I Chemicals 

Ephedrine, Pseudoephedrine, and 

Phenylpropanolamine for 2014 

AGENCY: Drug Enforcement 

Administration (DEA), Department of 

Justice. 

ACTION: Notice with request for 

comments. 

SUMMARY: The Drug Enforcement 

Administration proposes to adjust the 

2014 aggregate production quotas for 

several controlled substances in 

schedules I and II of the Controlled 

Substances Act and assessment of 

annual needs for the list I chemicals 

ephedrine, pseudoephedrine, and 

phenylpropanolamine. 

DATES: Interested persons may file 

written comments on this notice in 

accordance with 21 CFR 1303.11(c) and 

1315.11(d). Electronic comments must 

be submitted, and written comments 

must be postmarked, on or before July 

14, 2014. Commenters should be aware 

that the electronic Federal Docket 

Management System will not accept 

comments after midnight Eastern Time 

on the last day of the comment period. 

ADDRESSES: To ensure proper handling 

of comments, please reference ‘‘Docket 

No. DEA–378’’ on all electronic and 

written correspondence. The DEA 

encourages that all comments be 

submitted electronically through the 

Federal eRulemaking Portal at http://

www.regulations.gov. Paper comments 

that duplicate electronic submissions 

are not necessary. Should you, however, 

wish to submit written comments via 

regular or express mail, they should be 

sent to: Drug Enforcement 

Administration, Attention: DEA Federal 

Register Representative/ODW, 8701 

Morrissette Drive, Springfield, Virginia 

22152. 

FOR FURTHER INFORMATION CONTACT: 

Ruth A. Carter, Office of Diversion 

Control, Drug Enforcement 

Administration, 8701 Morrissette Drive, 

Springfield, Virginia 22152, Telephone: 

(202) 598–6812. 

SUPPLEMENTARY INFORMATION: 

Posting of Public Comments 

All comments received are considered 

part of the public record and will be 

made available for public inspection 

online at http://www.regulations.gov. 

Such information includes personal 

identifying information (such as your 

name, address, etc.) voluntarily 

submitted by the commenter. 

The Freedom of Information Act 

(FOIA) applies to all comments 

received. If you want to submit personal 

identifying information (such as your 

name, address, etc.) as part of your 

comment, but do not want it to be made 

publicly available, you must include the 

phrase ‘‘PERSONAL IDENTIFYING 

INFORMATION’’ in the first paragraph 

of your comment. You must also place 

all the personal identifying information 

you do not want made publicly 

available in the first paragraph of your 

comment and identify what information 

you want redacted. 

If you want to submit confidential 

business information as part of your 

comment, but do not want it to be made 

publicly available, you must include the 

phrase ‘‘CONFIDENTIAL BUSINESS 

INFORMATION’’ in the first paragraph 

of your comment. You must also 

prominently identify the confidential 

business information to be redacted 

within the comment. If a comment has 

so much confidential business 

information that it cannot be effectively 

redacted, all or part of that comment 

may not be made publicly available. 

Comments containing personal 

identifying information or confidential 

business information identified as 

directed above will be made publicly 

available in redacted form. 

An electronic copy of this document 

is available at http://

www.regulations.gov for easy reference. 

If you wish to personally inspect the 

comments and materials received or the 

supporting documentation the DEA 

used in preparing the proposed action, 

these materials will be available for 

public inspection by appointment. To 

arrange a viewing, please see the ‘‘For 

Further Information Contact’’ paragraph 

above. 

Legal Authority 

Section 306 of the Controlled 

Substances Act (CSA), 21 U.S.C. 826, 

requires the Attorney General to 

determine the total quantity and 

establish aggregate production quotas 

for each basic class of controlled 

substance listed in schedules I and II 

and for the list I chemicals ephedrine, 

pseudoephedrine, and 

phenylpropanolamine. This 

responsibility has been delegated to the 

Administrator of the DEA pursuant to 

28 CFR 0.100(b). The Administrator, in 

turn, has redelegated that authority to 

the Deputy Administrator, pursuant to 

28 CFR pt. 0 subpt. R, App. 

The DEA published the established 

aggregate production quotas for 

schedule I and II controlled substances 

and established assessment of annual 

needs for the list I chemicals ephedrine, 

pseudoephedrine, and 

phenylpropanolamine for 2014 in the 

Federal Register (78 FR 55099) on 

September 9, 2013. That notice 

stipulated that, in accordance with 21 

CFR 1303.13 and 1315.13, all aggregate 

production quotas and assessments of 

annual need are subject to adjustment. 

Analysis for Proposed Adjusted 2014 

Aggregate Production Quotas and 

Assessment of Annual Needs 

The DEA proposes to adjust the 

established 2014 aggregate production 

quotas for certain schedule I and II 

controlled substances to be 

manufactured in the United States in 

2014 to provide for the estimated 

medical, scientific, research, and 

industrial needs of the United States, for 

lawful export requirements, and for the 

establishment and maintenance of 

reserve stocks. These quotas do not 

include imports of controlled 

substances for use in industrial 

processes. The DEA also proposes to 

adjust the established 2014 assessment 

of annual needs for the list I chemicals 

ephedrine, pseudoephedrine, and 

phenylpropanolamine to be 

manufactured in and imported to the 

United States in 2014 to provide for the 

estimated medical, scientific, research, 

and industrial needs of the United 

States, lawful export requirements, and 

the establishment and maintenance of 

reserve stocks. 

In proposing the adjustment, the DEA 

has taken into account the criteria that 

the DEA is required to consider in 

accordance with 21 CFR 1303.13 and 21 

CFR 1315.13. The DEA determines 

whether to propose an adjustment of the 

aggregate production quotas for basic 

classes of schedule I and II controlled 

substances and assessment of annual 

needs for ephedrine, pseudoephedrine, 

and phenylpropanolamine by 

considering: (1) Changes in the demand 

for that class or chemical, changes in the 

national rate of net disposal of the class 

or chemical, and changes in the rate of 

net disposal of the class or chemical by 

registrants holding individual 

manufacturing quotas for the class; (2) 

whether any increased demand for that 

class or chemical, the national and/or 

individual rates of net disposal of that 

class or chemical are temporary, short 

term, or long term; (3) whether any 

increased demand for that class or 

chemical can be met through existing 

inventories, increased individual 

manufacturing quotas, or increased 


rmajette on DSK7SPTVN1PROD with NOTICES
Federal Register / Vol. 79, No. 113 / Thursday, June 12, 2014 / Notices 33781 

importation, without increasing the 

aggregate production quota; (4) whether 

any decreased demand for that class or 

chemical will result in excessive 

inventory accumulation by all persons 

registered to handle that class or 

chemical; and (5) other factors affecting 

medical, scientific, research, and 

industrial needs in the United States 

and lawful export requirements, as the 

Deputy Administrator finds relevant. 

The DEA also considered updated 

information obtained from 2013 yearend inventories, 2013 disposition data 

submitted by quota applicants, 

estimates of the medical needs of the 

United States, product development, 

and other information made available to 

the DEA after the initial aggregate 

production quotas and assessment of 

annual needs had been established. 

Other factors the DEA considered in 

calculating the aggregate production 

quotas, but not the assessment of annual 

needs, include product development 

requirements of both bulk and finished 

dosage form manufacturers, and other 

pertinent information. In determining 

the proposed adjusted 2014 assessment 

of annual needs, the DEA used the 

calculation methodology previously 

described in the 2010 and 2011 

established assessment of annual needs 

(74 FR 60294, Nov. 20, 2009, and 75 FR 

79407, Dec. 20, 2010, respectively). 

As described in the previously 

published notice establishing the 2014 

aggregate production quotas and 

assessment of annual needs, the DEA 

has specifically considered that 

inventory allowances granted to 

individual manufacturers may not 

always result in the availability of 

sufficient quantities to maintain an 

adequate reserve stock pursuant to 21 

U.S.C. 826(a), as intended. See 21 CFR 

1303.24. This would be concerning if a 

natural disaster or other unforeseen 

event resulted in substantial disruption 

to the amount of controlled substances 

available to provide for legitimate 

public need. As such, the DEA has 

included in all proposed adjusted 

schedule II controlled substance 

aggregate production quotas, and certain 

proposed adjusted schedule I controlled 

substance aggregate production quotas, 

an additional 25% of the estimated 

medical, scientific, and research needs 

as part of the amount necessary to 

ensure the establishment and 

maintenance of reserve stocks. The 

resulting adjusted established aggregate 

production quotas will reflect these 

included amounts. This action will not 

affect the ability of manufacturers to 

maintain inventory allowances as 

specified by regulation. The DEA 

expects that maintaining this reserve in 

certain established aggregate production 

quotas will mitigate adverse public 

effects if an unforeseen event resulted in 

substantial disruption to the amount of 

controlled substances available to 

provide for legitimate public need, as 

determined by the DEA. The DEA does 

not anticipate utilizing the reserve in 

the absence of these circumstances. 

The Deputy Administrator, therefore, 

proposes to adjust the 2014 aggregate 

production quotas for certain schedule I 

and II controlled substances and 

assessment of annual needs for the list 

I chemicals ephedrine, 

pseudoephedrine, and 

phenylpropanolamine, expressed in 

grams of anhydrous acid or base, as 

follows: 

Basic class 

Previously 

established 

2014 quotas 

(g) 

Proposed 

adjusted 2014 

quotas 

(g) 

Schedule I 

(1-Pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone (UR-144) .................................................... 15 No change.

[1-(5-Fluoro-pentyl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone (XLR11) ...................................... 15 No change. 

1-(1,3-Benzodioxol-5-yl)-2-(methylamino)butan-1-one (butylone) ........................................................................ 15 No change. 

1-(1,3-Benzodioxol-5-yl)-2-(methylamino)pentan-1-one (pentylone) .................................................................... 15 No change. 

1-(1-Phenylcyclohexyl)pyrrolidine ......................................................................................................................... 10 No change. 

1-(5-Fluoropentyl)-3-(1-naphthoyl)indole (AM2201) ............................................................................................. 45 No change. 

1-(5-Fluoropentyl)-3-(2-iodobenzoyl)indole (AM694) ............................................................................................ 45 No change. 

1-[1-(2-Thienyl)cyclohexyl]piperidine .................................................................................................................... 15 No change. 

1-[2-(4-Morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH-200) ................................................................................ 45 No change. 

1-Butyl-3-(1-naphthoyl)indole (JWH-073) ............................................................................................................. 45 No change. 

1-Cyclohexylethyl-3-(2-methoxyphenylacetyl)indole (SR-18 and RCS-8) ............................................................ 45 No change. 

1-Hexyl-3-(1-naphthoyl)indole (JWH-019) ............................................................................................................ 45 No change. 

1-Methyl-4-phenyl-4-propionoxypiperidine ............................................................................................................ 2 No change. 

1-Pentyl-3-(1-naphthoyl)indole (JWH-018 and AM678) ....................................................................................... 45 No change. 

1-Pentyl-3-(2-chlorophenylacetyl)indole (JWH-203) ............................................................................................. 45 No change. 

1-Pentyl-3-(2-methoxyphenylacetyl)indole (JWH-250) ......................................................................................... 45 No change. 

1-Pentyl-3-(4-chloro-1-naphthoyl)indole (JWH-398) ............................................................................................. 45 No change. 

1-Pentyl-3-(4-methyl-1-naphthoyl)indole (JWH-122) ............................................................................................ 45 No change. 

1-Pentyl-3-[(4-methoxy)-benzoyl]indole (SR-19, RCS-4) ..................................................................................... 45 No change. 

1-Pentyl-3-[1-(4-methoxynaphthoyl)]indole (JWH-081) ........................................................................................ 45 No change. 

2-(2,5-Dimethoxy-4-n-propylphenyl)ethanamine (2C-P) ....................................................................................... 30 No change. 

2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C-E) ............................................................................................ 30 No change. 

2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C-D) ......................................................................................... 30 No change. 

2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (2C-N) ........................................................................................... 30 No change. 

2-(2,5-Dimethoxyphenyl)ethanamine (2C-H) ........................................................................................................ 30 No change. 

2-(4-Bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25B-NBOMe; 2C-B-NBOMe; 25B; Cimbi36).15 No change. 

2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C-C) ......................................................................................... 30 No change. 

2-(4-Chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25C-NBOMe; 2C-C-NBOMe; 25C; 

Cimbi-82).

15 No change. 

2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C-I) ............................................................................................... 30 No change. 

2-(4-Iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25I-NBOMe; 2C-I-NBOMe; 25I; Cimbi-5) ... 15 No change. 

2-(Methylamino)-1-phenylpentan-1-one (pentedrone) .......................................................................................... 15 No change. 

2,5-Dimethoxy-4-ethylamphetamine (DOET) ....................................................................................................... 25 No change. 

2,5-Dimethoxy-4-n-propylthiophenethylamine ...................................................................................................... 25 No change. 


rmajette on DSK7SPTVN1PROD with NOTICES
33782 Federal Register / Vol. 79, No. 113 / Thursday, June 12, 2014 / Notices 

Basic class 

Previously 

established 

2014 quotas 

(g) 

Proposed 

adjusted 2014 

quotas 

(g) 

2,5-Dimethoxyamphetamine ................................................................................................................................. 25 No change. 

2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-2) ................................................................................. 30 No change. 

2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-4) ........................................................................... 30 No change. 

3,4,5-Trimethoxyamphetamine ............................................................................................................................. 25 No change. 

3,4-Methylenedioxyamphetamine (MDA) ............................................................................................................. 55 No change. 

3,4-Methylenedioxymethamphetamine (MDMA) .................................................................................................. 50 No change. 

3,4-Methylenedioxy-N-ethylamphetamine (MDEA) .............................................................................................. 40 No change. 

3,4-Methylenedioxy-N-methylcathinone (methylone) ........................................................................................... 50 No change. 

3,4-Methylenedioxypyrovalerone (MDPV) ............................................................................................................ 35 No change. 

3-Fluoro-N-methylcathinone (3-FMC) ................................................................................................................... 15 No change. 

3-Methylfentanyl .................................................................................................................................................... 2 No change. 

3-Methylthiofentanyl .............................................................................................................................................. 2 No change. 

4-Bromo-2,5-dimethoxyamphetamine (DOB) ....................................................................................................... 25 No change. 

4-Bromo-2,5-dimethoxyphenethylamine (2-CB) ................................................................................................... 25 No change. 

4-Fluoro-N-methylcathinone (4-FMC) ................................................................................................................... 15 No change. 

4-Methoxyamphetamine ....................................................................................................................................... 100 No change. 

4-Methyl-2,5-dimethoxyamphetamine (DOM) ....................................................................................................... 25 No change. 

4-Methylaminorex ................................................................................................................................................. 25 No change. 

4-Methyl-N-ethylcathinone (4-MEC) ..................................................................................................................... 15 No change. 

4-Methyl-N-methylcathinone (mephedrone) ......................................................................................................... 45 No change. 

4-Methyl-a-pyrrolidinopropiophenone (4-MePPP) ................................................................................................ 15 No change. 

5-(1,1-Dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol .......................................................................... 68 No change. 

5-(1,1-Dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (cannabicyclohexanol or CP-47,497 C8-homolog).53 No change. 

5-Methoxy-3,4-methylenedioxyamphetamine ....................................................................................................... 25 No change. 

5-Methoxy-N,N-diisopropyltryptamine ................................................................................................................... 25 No change. 

5-Methoxy-N,N-dimethyltryptamine ...................................................................................................................... 25 No change. 

Acetyl-alpha-methylfentanyl .................................................................................................................................. 2 No change. 

Acetyldihydrocodeine ............................................................................................................................................ 2 No change. 

Acetylmethadol ..................................................................................................................................................... 2 No change. 

Allylprodine ........................................................................................................................................................... 2 No change. 

Alphacetylmethadol ............................................................................................................................................... 2 No change. 

alpha-Ethyltryptamine ........................................................................................................................................... 25 No change. 

Alphameprodine .................................................................................................................................................... 2 No change. 

Alphamethadol ...................................................................................................................................................... 2 No change. 

alpha-Methylfentanyl ............................................................................................................................................. 2 No change. 

alpha-Methylthiofentanyl ....................................................................................................................................... 2 No change. 

alpha-Methyltryptamine (AMT) ............................................................................................................................. 25 No change. 

alpha-Pyrrolidinobutiophenone (a-PBP) ............................................................................................................... 15 No change. 

alpha-Pyrrolidinopentiophenone (a-PVP) ............................................................................................................. 15 No change.

Aminorex ............................................................................................................................................................... 25 No change. 

Benzylmorphine .................................................................................................................................................... 2 No change. 

Betacetylmethadol ................................................................................................................................................ 2 No change. 

beta-Hydroxy-3-methylfentanyl ............................................................................................................................. 2 No change. 

beta-Hydroxyfentanyl ............................................................................................................................................ 2 No change. 

Betameprodine ...................................................................................................................................................... 2 No change. 

Betaprodine ........................................................................................................................................................... 2 No change. 

Bufotenine ............................................................................................................................................................. 3 No change. 

Cathinone .............................................................................................................................................................. 70 No change. 

Codeine methylbromide ........................................................................................................................................ 5 No change. 

Codeine-N-oxide ................................................................................................................................................... 200 No change. 

Desomorphine ....................................................................................................................................................... 5 No change. 

Diethyltryptamine .................................................................................................................................................. 25 No change. 

Difenoxin ............................................................................................................................................................... 50 No change. 

Dihydromorphine ................................................................................................................................................... 3,990,000 No change. 

Dimethyltryptamine ............................................................................................................................................... 35 No change. 

Dipipanone ............................................................................................................................................................ 5 No change. 

Fenethylline ........................................................................................................................................................... 5 No change. 

gamma-Hydroxybutyric acid ................................................................................................................................. 70,250,000 No change. 

Heroin ................................................................................................................................................................... 25 No change. 

Hydromorphinol ..................................................................................................................................................... 2 No change. 

Hydroxypethidine .................................................................................................................................................. 2 No change. 

Ibogaine ................................................................................................................................................................ 5 No change. 

Lysergic acid diethylamide (LSD) ......................................................................................................................... 35 No change. 

Marihuana ............................................................................................................................................................. 650,000 No change. 

Mescaline .............................................................................................................................................................. 25 No change. 

Methaqualone ....................................................................................................................................................... 10 No change. 

Methcathinone ...................................................................................................................................................... 25 No change. 

Methyldesorphine .................................................................................................................................................. 2 No change. 

Methyldihydromorphine ......................................................................................................................................... 2 No change. 

Morphine methylbromide ...................................................................................................................................... 5 No change. 


rmajette on DSK7SPTVN1PROD with NOTICES
Federal Register / Vol. 79, No. 113 / Thursday, June 12, 2014 / Notices 33783 

Basic class 

Previously 

established 

2014 quotas 

(g) 

Proposed 

adjusted 2014 

quotas 

(g) 

Morphine methylsulfonate ..................................................................................................................................... 5 No change. 

Morphine-N-oxide ................................................................................................................................................. 175 No change. 

N-(1-Adamantyl)-1-pentyl-1H-indazole-3-carboxamide (AKB48) ......................................................................... 15 No change. 

N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide (ADB-PINACA) ...................... 15 No change. 

N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide (AB-FUBINACA) ........... 15 No change. 

N,N-Dimethylamphetamine ................................................................................................................................... 25 No change. 

Naphthylpyrovalerone (naphyrone) ...................................................................................................................... 15 No change. 

N-Benzylpiperazine ............................................................................................................................................... 25 No change. 

N-Ethyl-1-phenylcyclohexylamine ......................................................................................................................... 5 No change. 

N-Ethylamphetamine ............................................................................................................................................ 24 No change. 

N-Hydroxy-3,4-methylenedioxyamphetamine ....................................................................................................... 24 No change. 

Noracymethadol .................................................................................................................................................... 2 No change. 

Norlevorphanol ...................................................................................................................................................... 52 No change. 

Normethadone ...................................................................................................................................................... 2 No change. 

Normorphine ......................................................................................................................................................... 18 No change. 

para-Fluorofentanyl ............................................................................................................................................... 2 No change. 

Parahexyl .............................................................................................................................................................. 5 No change. 

Phenomorphan ..................................................................................................................................................... 2 No change. 

Pholcodine ............................................................................................................................................................ 2 No change. 

Properidine ............................................................................................................................................................ 2 No change. 

Psilocybin .............................................................................................................................................................. 30 40 

Psilocyn ................................................................................................................................................................. 30 50 

Quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate (5-fluoro-PB-22; 5F-PB-22) ......................................... 15 No change. 

Quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate (PB-22; QUPIC) ......................................................................... 15 No change. 

Tetrahydrocannabinols ......................................................................................................................................... 491,000 No change. 

Thiofentanyl .......................................................................................................................................................... 2 No change. 

Tilidine ................................................................................................................................................................... 10 No change. 

Trimeperidine ........................................................................................................................................................ 2 No change. 

Schedule II 

1-Phenylcyclohexylamine ..................................................................................................................................... 3 No change. 

1-Piperidinocyclohexanecarbonitrile ..................................................................................................................... 3 No change. 

4-Anilino-N-phenethyl-4-piperidine (ANPP) .......................................................................................................... 2,687,500 No change. 

Alfentanil ............................................................................................................................................................... 17,625 No change. 

Alphaprodine ......................................................................................................................................................... 3 No change. 

Amobarbital ........................................................................................................................................................... 9 No change. 

Amphetamine (for conversion) ............................................................................................................................. 18,375,000 No change. 

Amphetamine (for sale) ........................................................................................................................................ 49,000,000 No change. 

Carfentanil ............................................................................................................................................................. 19 No change. 

Cocaine ................................................................................................................................................................. 240,000 No change. 

Codeine (for conversion) ...................................................................................................................................... 68,750,000 No change. 

Codeine (for sale) ................................................................................................................................................. 46,125,000 No change. 

Dextropropoxyphene ............................................................................................................................................. 19 No change. 

Dihydrocodeine ..................................................................................................................................................... 100,750 No change. 

Diphenoxylate ....................................................................................................................................................... 750,000 1,288,750 

Ecgonine ............................................................................................................................................................... 144,000 174,375 

Ethylmorphine ....................................................................................................................................................... 3 No change. 

Fentanyl ................................................................................................................................................................ 2,108,750 No change. 

Glutethimide .......................................................................................................................................................... 3 No change. 

Hydrocodone (for conversion) .............................................................................................................................. 0 137,500 

Hydrocodone (for sale) ......................................................................................................................................... 99,625,000 No change. 

Hydromorphone .................................................................................................................................................... 6,750,000 No change. 

Isomethadone ....................................................................................................................................................... 5 No change. 

Levo-alphacetylmethadol (LAAM) ......................................................................................................................... 4 No change. 

Levomethorphan ................................................................................................................................................... 195 No change. 

Levorphanol .......................................................................................................................................................... 2,000 4,625 

Lisdexamfetamine ................................................................................................................................................. 23,750,000 No change. 

Meperidine ............................................................................................................................................................ 6,250,000 No change. 

Meperidine Intermediate-A ................................................................................................................................... 6 No change. 

Meperidine Intermediate-B ................................................................................................................................... 11 No change. 

Meperidine Intermediate-C ................................................................................................................................... 6 No change. 

Metazocine ............................................................................................................................................................ 19 No change. 

Methadone (for sale) ............................................................................................................................................ 31,875,000 No change. 

Methadone Intermediate ....................................................................................................................................... 38,875,000 No change. 

Methamphetamine ................................................................................................................................................ 2,811,375 No change. 

[1,250,000 grams of levo-desoxyephedrine for use in a non-controlled, non-prescription product; 1,500,000 grams for methamphetamine mostly 

for conversion to a schedule III product; and 61,375 grams for methamphetamine (for sale)] 

Methylphenidate .................................................................................................................................................... 96,750,000 No change. 

Morphine (for conversion) ..................................................................................................................................... 91,250,000 No change. 


rmajette on DSK7SPTVN1PROD with NOTICES
33784 Federal Register / Vol. 79, No. 113 / Thursday, June 12, 2014 / Notices 

Basic class 

Previously 

established 

2014 quotas 

(g) 

Proposed 

adjusted 2014 

quotas 

(g) 

Morphine (for sale) ............................................................................................................................................... 62,500,000 No change. 

Nabilone ................................................................................................................................................................ 30,375 No change. 

Noroxymorphone (for conversion) ........................................................................................................................ 17,500,000 No change. 

Noroxymorphone (for sale) ................................................................................................................................... 1,262,500 No change. 

Opium (powder) .................................................................................................................................................... 112,500 No change. 

Opium (tincture) .................................................................................................................................................... 625,000 No change. 

Oripavine ............................................................................................................................................................... 22,750,000 27,625,000 

Oxycodone (for conversion) ................................................................................................................................. 9,250,000 No change. 

Oxycodone (for sale) ............................................................................................................................................ 149,375,000 No change. 

Oxymorphone (for conversion) ............................................................................................................................. 25,000,000 No change. 

Oxymorphone (for sale) ........................................................................................................................................ 7,750,000 No change. 

Pentobarbital ......................................................................................................................................................... 35,000,000 No change. 

Phenazocine ......................................................................................................................................................... 6 No change. 

Phencyclidine ........................................................................................................................................................ 19 No change. 

Phenmetrazine ...................................................................................................................................................... 3 No change. 

Phenylacetone ...................................................................................................................................................... 67,000,000 45,750,000 

Racemethorphan .................................................................................................................................................. 3 No change. 

Remifentanil .......................................................................................................................................................... 3,750 5,875 

Secobarbital .......................................................................................................................................................... 215,003 No change. 

Sufentanil .............................................................................................................................................................. 6,255 No change. 

Tapentadol ............................................................................................................................................................ 17,500,000 No change. 

Thebaine ............................................................................................................................................................... 145,000,000 No change. 

List I Chemicals 

Ephedrine (for conversion) ................................................................................................................................... 1,000,000 No change. 

Ephedrine (for sale) .............................................................................................................................................. 3,000,000 No change. 

Phenylpropanolamine (for conversion) ................................................................................................................. 44,800,000 No change. 

Phenylpropanolamine (for sale) ............................................................................................................................ 5,300,000 No change. 

Pseudoephedrine (for conversion) ....................................................................................................................... 5,000 No change. 

Pseudoephedrine (for sale) .................................................................................................................................. 192,000,000 224,500,000 

The Deputy Administrator further 

proposes that aggregate production 

quotas for all other schedule I and II 

controlled substances included in 21 

CFR 1308.11 and 1308.12 remain at 

zero. Pursuant to 21 CFR 1303.13 and 21 

CFR 1315.13, upon consideration of the 

relevant factors, the Deputy 

Administrator may adjust the 2014 

aggregate production quotas and 

assessment of annual needs as needed. 

Comments 

Pursuant to 21 CFR 1303.11(c) and 

1315.11(d), any interested person may 

submit written comments on or 

objections to these proposed 

determinations. Based on comments 

received in response to this notice, the 

Deputy Administrator may hold a 

public hearing on one or more issues 

raised. 21 CFR 1303.11(c) and 

1515.11(e). In the event the Deputy 

Administrator decides to hold such a 

hearing, the Deputy Administrator will 

publish a notice of the hearing in the 

Federal Register. After consideration of 

any comments or objections, or after a 

hearing, if one is held, the Deputy 

Administrator will issue and publish in 

the Federal Register a final order 

establishing any adjustment of 2014 

aggregate production quota for each 

basic class of controlled substance and 

established assessment of annual needs 

for the list I chemicals ephedrine, 

pseudoephedrine, and 

phenylpropanolamine. 21 CFR 

1303.11(c) and 1315.11(f). 

Dated: June 4, 2014. 

Thomas M. Harrigan, 

Deputy Administrator. 

[FR Doc. 2014–13804 Filed 6–11–14; 8:45 am] 

BILLING CODE 4410–09–P 

OFFICE OF MANAGEMENT AND 

BUDGET 

Fiscal Year 2014 Cost of Hospital and 

Medical Care Treatment Furnished by 

the Department of Defense Medical 

Treatment Facilities; Certain Rates 

Regarding Recovery From Tortiously 

Liable Third Persons 

AGENCY: Executive Office of the 

President, Office of Management and 

Budget. 

ACTION: Notice. 

SUMMARY: By virtue of the authority 

vested in the President by Section 2(a) 

of Pub. B. 87–603 (76 Stat. 593; 42 

U.S.C. 2652), and delegated to the 

Director of the Office of Management 

and Budget by the President through 

Executive Order No. 11541 of July 1, 

1970, the rates referenced below are 

hereby established. These rates are for 

use in connection with the recovery 

from tortiously liable third persons for 

the cost of inpatient medical services 

furnished by military treatment facilities 

through the Department of Defense 

(DoD). The rates have been established 

in accordance with the requirements of 

OMB Circular A–25, requiring 

reimbursement of the full cost of all 

services provided. The FY14 inpatient 

medical rates referenced are effective 

upon publication of this notice in the 

Federal Register and will remain in 

effect until further notice. Previously 

published outpatient medical and 

dental, and cosmetic surgery rates 

remain in effect until further notice. 

Pharmacy rates are updated 

periodically. A full disclosure of the 

rates is posted on DoD’s Uniform 

Business Office Web site: http://

www.tricare.mil/ocfo/mcfs/ubo/mhs_

rates.cfm. 

Brian C. Deese, 

Deputy Director. 

[FR Doc. 2014–13687 Filed 6–11–14; 8:45 am] 

BILLING CODE P 


rmajette on DSK7SPTVN1PROD with NOTICES